Related Experiment Video
Updated: Jul 4, 2025
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
Propofol Modulates Gallbladder Cancer Progression via miR-4430/SLC19A3 Axis
Background/Aim:
Propofol is a common anesthetic used during surgery. MircoRNA (miRNA), especially miR-4430, is currently a research hotspot in GBC. This study investigates whether propofol regulates GBC through the miR-4430/SLC19A3 axis.
Materials And Methods:
NOZ and SGC996 cells, human gallbladder cancer cell lines, were obtained from BLUEFBIO (Shanghai, China). The cells were treated with propofol, and the experimental setup included a control group. qRT-PCR was used to measure the content of miR-4430 and solute carrier family 19 member 3 (SLC19A3). The cell viability, migration, and apoptosis were analyzed by colony formation assay, wound healing assay, and flow cytometry, respectively. Western blot tested the levels of SLC91A3, cyclin D-dependent kinases 6 (CDK6), and Bax proteins. Mechanically, dual-luciferase reporter assay notarized the link of miR-4430 with SLC19A3.
Results:
Propofol significantly repressed the proliferation of GBC cells, as indicated by a pronounced reduction in colony formation in both NOZ and SGC996 cells (P = .025, 95% CI:1.2, 2.4). The inhibitory effect of propofol was reversed by the enhanced expression of miR-4430 in GBC cells. Furthermore, SLC19A3 was identified as a direct target of miR-4430. Silencing SLC19A3 reversed the altered cell behavior observed in propofol-treated GBC cells (P = .019, 95% CI:1.6, 3.5). Additionally, overexpression of SLC19A3 significantly attenuated both cell proliferation and migration influenced by miR-4430 in propofol-treated GBC cells (P = .034, 95% CI:1.4, 2.8).
Conclusion:
Propofol changed the cell behaviors of GBC by modulating the miR-4430/SLC19A3 axis.
Insights
Propofol, a common anesthetic, inhibits gallbladder cancer (GBC) cell proliferation by regulating miR-4430 and its target SLC19A3. This study reveals a novel mechanism for propofol's action in GBC treatment.
Area of Science:
- Oncology
- Molecular Biology
- Anesthesiology
Background:
- Gallbladder cancer (GBC) is a significant health concern.
- MicroRNA (miRNA), specifically miR-4430, is a key factor in GBC research.
- Propofol, a widely used anesthetic, is investigated for its potential role in GBC regulation.
Purpose of the Study:
- To investigate the regulatory role of propofol in GBC.
- To elucidate the involvement of the miR-4430/SLC19A3 axis in propofol's effects on GBC.
- To determine if propofol modulates GBC cell behavior via this specific molecular pathway.
Main Methods:
- Utilized human GBC cell lines (NOZ and SGC996).
- Treated cells with propofol and measured miR-4430 and SLC19A3 expression via qRT-PCR.
- Assessed cell viability, migration, and apoptosis using colony formation, wound healing, and flow cytometry assays.
- Confirmed the miR-4430 and SLC19A3 interaction using dual-luciferase reporter assay.
Main Results:
- Propofol significantly repressed GBC cell proliferation (P = .025).
- miR-4430 expression reversed propofol's inhibitory effects.
- SLC19A3 was identified as a direct target of miR-4430, and its silencing reversed propofol-induced GBC cell alterations (P = .019).
- Overexpression of SLC19A3 attenuated proliferation and migration in propofol-treated GBC cells (P = .034).
Conclusions:
- Propofol exerts its effects on GBC cell behavior by modulating the miR-4430/SLC19A3 axis.
- This pathway represents a potential therapeutic target for GBC.
